Kemal Malik

Type: Person

Name: Kemal Malik

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

Promising Phase III Results for Regeneron, Bayer mCNV Candidate

Regeneron Pharmaceuticals and Bayer HealthCare today report positive top-line Phase III results for their EYLEA® (aflibercept) injection for the treatment of myopic choroidal neovascularization (mCNV).The companies said that participants in the MYRROR ... [Published Genetic Engineering News - Jun 06 2013]

Entities: Regeneron, Bayer AG, Eylea, Phase III, Bayer HealthCare

First reported May 31 2013 - Updated May 31 2013 - 1 reports

Bayer AG

Bayer seeks regulatory approval for hypertension drug in Japan

Bayer HealthCare has filed the oral investigational drug riociguat for the treatment of chronic thromboembolic pulmonary hypertension, or CTEPH, for regulatory approval in Japan. "To date, there is no pharmacological treatment available for CTEPH. There ... [Published Individual.com - May 31 2013]

Entities: Bayer AG, Bayer HealthCare, Hypertension

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Phase III trial of regorafenib in patients with advanced liver cancer

Bayer HealthCare has announced that the company has started to enrol patients in an international Phase III trial to evaluate the efficacy and safety of regorafenib for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed ... [Published Hospital Pharmacy Europe - May 21 2013]

Entities: regorafenib, Liver Cancer, Phase III, Patient, Sorafenib

First reported Feb 03 2013 - Updated Feb 03 2013 - 1 reports

A New Unmet Medical Need: Excess Adipose Tissue Syndrome

As reported by FierceBiotech ( here ), "Bayer Healthcare touted upbeat data from a pair of late-stage studies of an investigational drug [ATX-101, a synthetic version of a human bile component] targeting chin fat, setting the stage for the giant to step ... [Published Pharma Marketing Blog - Feb 03 2013]

Entities: Bayer AG, Botox, Bayer HealthCare, Drugs, Kemal Malik

More Content

sort by: Date \| Relevance
Regeneron and Bayer Report Positive Phase 3 Res... [Published KLFY - Jun 15 2013]
Bayer and Onyx report positive data from Phase ... [Published Individual.com - Jun 11 2013]
Promising Phase III Results for Regeneron, Baye... [Published Genetic Engineering News - Jun 06 2013]
REGENERON: Study Shows Eylea Improves Vision Ac... [Published 4 Traders - Jun 06 2013]
Regeneron and Bayer Report Positive Phase 3 Res... [Published Yahoo! Finance - Jun 06 2013]
Regeneron and Bayer Report Positive Phase 3 Res... [Published ADVFN UK - Jun 06 2013]
Regeneron and Bayer Report Positive Phase 3 Res... [Published Staten Island Live - Jun 06 2013]
Bayer HealthCare receives EU approval for acute... [Published Individual.com - Jun 05 2013]
Bayer announces positive data from Phase III PA... [Published Individual.com - Jun 04 2013]
Sorafenib (Nexavar) Delays Rare Thyroid Cancer ... [Published MediLexicon - Jun 03 2013]
Onyx Phase 3 Nexavar DECISION Trial Shows Signi... [Published Benzinga.com - Jun 02 2013]
Phase 3 DECISION Trial Investigating the Use of... [Published ADVFN UK - Jun 02 2013]
Bayer seeks regulatory approval for hypertensio... [Published Individual.com - May 31 2013]
Bayer HealthCare initiates Phase III hepatocell... [Published Individual.com - May 30 2013]
Bayer HealthCare receives FDA approval for pros... [Published Individual.com - May 30 2013]
Bayer wins EU approval for Xarelto in ACS [Published PMLive - May 28 2013]
Xarelto® approved in the EU for secondary preve... [Published Hospital Pharmacy Europe - May 28 2013]
European Commission approves Bayerâs Xarelto fo... [Published PharmaBiz - May 27 2013]
Bayer bolsters campaign for PAH drug riociguat ... [Published FierceBiotech - May 21 2013]
Phase III trial of regorafenib in patients with... [Published Hospital Pharmacy Europe - May 21 2013]
BAYER AG: Bayer Presents Positive Interim Resul... [Published 4 Traders - May 21 2013]
Bayer HealthCare enrolls 1st patient in INHALE ... [Published PharmaBiz - Apr 18 2013]
Bayerâs pulmonary hypertension drug riociguat g... [Published PharmaBiz - Apr 09 2013]
Bayer receives Japanese approval for Stivarga t... [Published PharmaBiz - Mar 28 2013]
Bayer's sNDA for oral anticoagulant Xarelto get... [Published PharmaBiz - Mar 06 2013]
Trial will evaluate aflibercept to treat DME in... [Published Modern Medicine - Feb 22 2013]
Regeneron, Bayer begin phase III trial of EYLEA... [Published PharmaBiz - Feb 20 2013]
US FDA grants priority review status to Bayer's... [Published PharmaBiz - Feb 15 2013]
Bayer HealthCare, Janssen ink clinical collabor... [Published PharmaBiz - Feb 07 2013]
A New Unmet Medical Need: Excess Adipose Tissue... [Published Pharma Marketing Blog - Feb 03 2013]